Department of Medical Genetics, Medical School, University of Athens, Greece

Similar documents
Hospital Universitario de Getafe (Getafe Universitary Hospital), Spain

The Centre for Disease Prevention and Control, Latvia

Central Manchester University Hospitals NHS Foundation Trust, UK

Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN

Ministry for Health, the Elderly and Community Care, Malta

National Center for Tumor Diseases (NCT) Heidelberg, Germany

RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain

Hospital Carlos Haya. Malaga, Spain

INSTITUTE OF CHILD HEALTH, Greece

Radboud University Nijmegen Medical Centre, department of Neurology, Netherlands

European Society of Cardiology, France

Schoen Kliniken group, Schoen Klinik Hamburg Eilbek, Dept. of neurology and. neurorehabilitation, Germany

SERVICIO DE NEUROCIRUGÍA PEDIÁTRICA. HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Spain

Cystic Fibrosis Europe (CFE), Germany

Castilla y leon Regional Health Service (Gerencia Regional de Salud de Castilla y León)

Erasmus MC, Center for lysosomal and metabolic diseases, Netherlands

Riga East University hospital stationary Infectology Center of Latvia (RAKUS LIC), Latvia

VSOP, Lupus Netherlands

European Haemophilia Consortium

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

ERN board of Member States

National Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health

European Reference Networks: strategic value for the Member States. Perspective of France

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

European Reference Networks (ERN) Guide for patient advocates

Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016

WORK PLAN 2017 LAURENCE BALLIEUX NATIONAL FOCAL POINT. 1 EU 3rd HEALTH PROGRAMME

BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)

ERN Assessment Manual for Applicants

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

A short paper for ENVI & IMCO MEPs Two solutions to improve recognition of specialisms in the Chapter III professions

SCHEDULE 2 THE SERVICES

Council, 25 September 2014

Executive Report to the European Commission on newborn screening in the European Union

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Report on the interim evaluation of the «Daphne III Programme »

Education and Training Committee, 5 June 2014

The Seventh Framework Programme for candidate and potential candidate countries European Regional Economic Forum Nova Gorica, 30 May 2007

Jean Monnet support to associations

Do terms like FP6, CORDIS, Specific Programme, Call for

European Quality Assurance Scheme for Breast Cancer Services

The following passage wants to illustrate the insufficiencies in CF care the patients, their families and care giver struggle with:

Erasmus+ Programme Jean Monnet Activities. Snejina Nikolova Education, Audiovisual and Culture Executive Agency (EACEA)

Erasmus for Young Entrepreneurs

Background paper. Cross-border healthcare in the EU

Spreading Excellence and Widening Participation in Horizon 2020

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

116 Help Lines for Rare Diseases

10 Specialist commissioning

Current trends in European microbiology

The European network evaluation of the PHAR QA framework of competences for...

Introduction to ibmg. Marco Varkevisser Director of Education

A European workforce for call centre services. Construction industry recruits abroad

Supportive Care Roundtable

The clinical scientist in pathology. March 2005

The European Research Council. ERC and Greece. FP7 achievements and H2020 results. January Theodore PAPAZOGLOU ERCEA Head of Unit A.

Call for Nominations. CARLOS V European Award

International dimension of Higher Education 27/06/2015

ANNEX I TO VIII ANNEX I. Health Programme Work Programme for 2017

REFLECTION PROCESS on CHRONIC DISEASES INTERIM REPORT

ERC Grant Schemes. Horizon 2020 European Union funding for Research & Innovation

Implementing the 3rd Health Programme. Ingrid Keller Coordinator Health Programme Consumer, Health and Food Executive Agency

EUCERD Joint Action WP7 Workshop From Centres of Expertise for Rare Diseases to European Reference Networks

2nd European Reference Networks Conference 8-9 October Lisbon, Portugal. A report by: G Porto & F Courtois

CALL TEXT AND NATIONAL/REGIONAL REGULATIONS

Copernicus Incubation Programme

Presentation of Interreg Europe

Call for the expression of interest Selection of six model demonstrator regions to receive advisory support from the European Cluster Observatory

Healthcare Science Assistant

FP7: Marie Curie Actions

Overview on diabetes policy frameworks in the European Union and in other European countries

Document: Report on the work of the High Level Group in 2006

Presenting the European Investment Advisory Hub Annual Forum of the EUSDR, 2015 Ulm. European Investment Advisory Hub 1

Current and future standardization issues in the e Health domain: Achieving interoperability. Executive Summary

Assessment of Erasmus+ Sports

Building the Europe of Knowledge

Hospital Pharmacists making the difference in medication use

Erasmus Mundus José Gutiérrez Fernández Erasmus Mundus Programme Coordinator EACEA

Developing a European Registry for Rare Anaemias

Regulatory Cooperation in Europe. Natalie McCoy, CEER Secretary General INOGATE Conference - Brussels, 1 February 2013

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

European Policy Experimentations

THE GLOBAL RESEARCH ENVIRONMENT HOW MIGHT AUSTRALIA PARTICIPATE MORE EFFECTIVELY?

Summary of a Survey on the Europe 2020 Flagship Initiative Innovation Union. Executive Summary

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

A shared agenda for growth: European Commission Services

Erasmus+ Work together with European higher education institutions. Piia Heinämäki Erasmus+ Info Day, Lviv Erasmus+

Implementation Plan for the UK Strategy for Rare Diseases

Annex 3 Information and Communication Requirements EEA and Norway Grants

Guidance for the Applicants: Gilead Sciences Nordic Fellowship Programme 2017

TUITION FEE GUIDANCE FOR ERASMUS+ EXCHANGE STUDENTS Academic Year

Guideline for Applicants. Intramural Research Funding Programs Faculty of Medicine Tübingen

Mental Health Reform: the Greek Experience

CaixaImpulse Form 2017

ECHA Helpdesk Support to National Helpdesks

Simona Bovha, CPCM European Investment Bank. European Investment Advisory Hub

Info Session Webinar Joint Qualifications in Vocational Education and Training Call for proposals EACEA 27/ /10/2017

QUICK REFERENCE TO CALDICOTT & THE DATA PROTECTION ACT 1998 PRINCIPLES

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

Transcription:

Department of Medical Genetics, Medical School, University of Athens, Greece 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: Please indicate what type: 1. Respondent Profile Healthcare provider In hospital specialised service or unit 1.1.1. Other (please specify): Ag. Sophia Children's hospital. University of Athens 1.2 Please indicate the name of your organisation or centre: Department of Medical Genetics, Medical School, University of Athens 1. Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: 1. Please indicate the number of EU Member States and EEA countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 1.5 If need be, can we contact you by e-mail to obtain further information on your submission? 1.5.1 Please provide an e-mail address where we can contact you: ekanavak@med.uoa.gr EL 1 1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): Emmanuel Kanavakis Professor - Head of the Department of Medical Genetics Medical School, University of Athens phone number +0210-779555 1.7 Please provide additional contact details if needed: Department fo Medical Genetics, Choremio Research Laboratory "Ag. Sophia" Children's Hospital Thivon&Livadias Str. 11527 Athens, Greece

2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? 2.1.1 Space for further comments: 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) High Highly specialised healthcare provision Professional performance, clinical practice, quality and safety of specialized healthcare 2.2.1. Space for further comments: 2. Is highly specialised healthcare a priority in your organisation's strategies and work plans? 2..1 Space for further comments: 2.. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? Very high Laboratories and central services (e.g. pathology, genetics, biochemistry, pharmacy, microbiology etc.) Please specify: 2.5. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? Clinical evaluation - Laboratory Medical Genetics Occasionally 2.5.1 Please describe your role in such actions/projects: 2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare?

2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: 2.8. Is your centre or unit directly involved in the management (diagnosis, treatment etc.) of highly specialised diseases or conditions? 2.9. Is your centre or unit designated or recognised as centre of reference/excellence in your country? 2.10. How has your centre been designated/recognised as centre of reference/excellence? Through a formal institutional process 2.10.1 Space for further comments: 2.11. Which is your area of expertice as centre of reference? (please provide your answer in free text) Genetic testing for common and rare genetic disorders Clinical evaluation of individuals with multiple phenotypic abnormalities and/or mental retardation and / or autism Genetic Counselling 2.12 Is your centre participating currently in a network of centres of expertise? 2.1. What is the scope of the network? International 2.1. Which kind of network? Founded by other sources 2.1.1 Space for further comments:

2.15. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, 5 = very interested) 2.15.1 Space for further comments:. Proposed criteria for ERN (scope, general and specific criteria).1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN.1.1. Need of highly specialised healthcare.1.1.1. Complexity of the diagnosis and treatment 5.1.1.2. High cost of treatment and resources 5.1.1.. Need of advanced/highly specialised medical equipment or infrastructures.1.2. Need of particular concentration of expertise and resources.1.2.1. Rare expertise/need of concentration of cases.1.2.2. Low prevalence/incidence/number of cases.1.2.. Evaluated experiences of Member States.1.. Based on high-quality, accessible and cost-effective healthcare.1..1. Evidence of the safety and favourable risk-benefit analysis 5 5

.1..2. Feasibility and evidence of the value and potential positive outcome (clinical).1.. Do you recommend any additional criteria or option that would effectively address the issue? No.1.5. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria?.1.5.1 Explain your proposal in free text: 1. Creation of CF registry 2. General population screening for the identification of CF and SMA carriers..2. General criteria of the centres wishing to join a European Reference Network.2.1. Organisation and management 5.2.2. Patients empowerment and centered care.2.. Patient care, clinical tools and health technology assessment.2.. Quality, patient safety and evaluation framework policies.2.5. Business continuity, contingency planning and response capacity.2.6. Information systems, technology and e-health tools and applications.2.7. Overall framework and capacity for research and training.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN

.2.9. Do you recommend any additional option that would effectively address the issue?.2.9.1. Space for further comments: No..1. Competence, experience and good outcomes and care 5.. Specific criteria regarding the areas of expertise..2. Specific resources and organisation:..2.1. Human resources..2.2. Team/centre organisation..2.. Structural conditions..2.. Specific equipment..2.5. Presence and coordination with other required complementary units or services... Patient care pathways, protocols and clinical guidelines in the field of expertise... External coordination, care management and follow-up of patients..5. Research, training, health technology assessment in the field of expertise..6. Specific information systems 5..7. Do you recommend any additional criteria or option that would effectively address the issue?..7.1. Space for further comments: c No